Syngene Share: Dips despite completes $36.5 Mn US biologics site acquisition
Despite announcing the completion of its first biologics site acquisition in the US, Syngene, the contract research arm of Biocon, saw its shares dip 0.42
Despite announcing the completion of its first biologics site acquisition in the US, Syngene, the contract research arm of Biocon, saw its shares dip 0.42